Is Biogen a Risky Stock?

Industry Focus' crew tries to figure out whether Biogen will reward investors in 2017.

2016's Worst Clinical Failures

It's been a rough year for drugmakers, but late clinical-stage failures made it especially tough ...

3 Reasons to Sell Biogen

Increasing competition within the multiple sclerosis market makes Biogen king of a crumbling empi...

3 Reasons To Buy Biogen

Drugs in Biogen's pipeline and top-shelf financials could mean that Biogen's future may not be as...